Architectural analysis of subconjunctival oblique limbus incision techniques in manual cataract extraction surgery by optical coherence tomography imaging

The purpose was to assess the profile of subconjunctival oblique limbus incision (SCOLI) design by using anterior-segment optical coherence tomography (AS-OCT) and try to emphasize the proper technique of wound construction. The structural dimensions and integrity of the wound were acquired from the patients, who had undergone manual small-incision cataract surgery with SCOLI techniques, using a Canon OCT anterior-segment imaging system on the first postoperative day. The use of AS-OCT allowed for an in vivo evaluation of SCOLI in high definition. The radial OCT scan image showed three staggered incisions, including conjunctiva incision, scleral entrance, and inner corneal lip. A tangential scan demonstrated that the internal lip is parallel to the curvature of the peripheral cornea. The en face image showed an asymmetric 4 arc-shaped configuration rather than a symmetrical one. In conclusion, AS-OCT could be used to analyze SCOLI to determine optimal wound construction and geometry. The results of this study indicated that an asymmetric 4 arc-shaped limbus tunnel incision was superior to the conventional linear equivalent in stability and nucleus delivery.     

用纵向队列法分析昆明地区体检人群同型半胱氨酸对血压、血糖及血脂的影响

目的 通过纵向队列研究分析同型半胱氨酸(homocysteine,Hcy)对血压、血糖及血脂变化的影响,为相关慢性疾病的防治提供依据.方法 选取在2017年基线调查之后2 a期间每年体检调查中具有完整资料的体检人员987人作为研究对象,构建纵向研究队列,收集其基本信息、Hcy、空腹血糖、空腹血脂以及血压测量结果.根据末...     

干扰CD151基因表达对裸鼠宣威肺腺癌XWLC-05细胞肺转移的影响

目的 探讨RNA干扰抑制CD151基因表达对宣威肺腺癌XWLC-05细胞侵袭和迁移的影响及裸鼠肺转移的实验。方法 构建能高效抑制CD151基因表达的3组重组干扰质粒,筛选出稳定转染干扰质粒的宣威肺腺癌XWLC-05细胞株。MTT、划痕实验、Transwell实验研究干扰CD151基因表达前后对细胞迁移和侵袭的影响。将构建的RNA干扰抑制CD151基因表达的稳转细胞XWLC-05-shRNA、XWLC-05-shNC、XWLC-05-Blank通过尾静脉注射入BALB/c裸鼠,30天后通过肉眼和HE染色后观察肺转移情况。结果 划痕实验和Transwell实验表明RNA干扰抑制CD151基因表达可能抑制宣威肺腺癌XWLC-05细胞体外迁移和侵袭作用（P<0.05）。XWLC-05-shRNA、XWLC-05-shNC、XWLC-05-Blank各组裸鼠肺转移率及肺组织上的转移病灶数依次为75%（6/8）与（5.2±1.2）、100%（8/8）与（9.8±1.6）、87.5%（7/8）与（9.1±1.2）。XWLC-05-shNC与XWLC-05-Blank组比较差异无统计学意义（P=0.423）,XWLC-05-shRNA与XWLC-05-shNC（P=0.000）和XWLC-05-Blank组比较差异有统计学意义（P=0.000）。结论 RNA干扰抑制CD151基因表达能抑制XWLC-05细胞的体外迁移和侵袭;能减少XWLC-05细胞裸鼠的肺转移。CD151可能成为抑制宣威肺癌侵袭和迁移的潜在治疗靶点之一。     

环氧化酶2基因-765G／C多态性与昆明地区汉族2型糖尿病患者糖尿病肾病发生、发展的关系

目的 探讨环氧化酶2基因启动子区-765G/C多态性与昆明地区汉族2型糖尿病患者糖尿病肾病发生、发展的相关性.方法 选取2008年1月至12月昆明医学院第一附属医院糖尿病科收治住院的2型糖尿病患者252例,根据24 h尿白蛋白排泄率或随机尿白蛋白/肌酐比值分至无糖尿病肾病组（n=100）、隐性糖尿病肾病组（n=78）、显性糖尿病肾病组（n=74）.运用聚合酶链反应-限制性片段长度多态性方法检测环氧化酶2基因启动子区-765G/C多态性.检测血糖、血脂和其他生化指标.运用χ^2检验比较各组基因型频率和等位基因频率,运用方差分析比较各组相关临床及生化指标,采用logistic回归分析评价影响糖尿病肾病发生、发展的危险因素.结果 两糖尿病肾病组-765GG基因型频率与无糖尿病肾病组存在明显差异（0.901 vs 0.810;χ^2=4.309,P＜0.05）.糖尿病肾病患者中,-765GG基因型携带者空腹血糖、餐后2 h血糖与非携带者存在明显差异[分别为（7.9±4.0）vs（5.9±1.7）mmol/L,（12±5）vs（9±4）mmol/L;t值分别为0.001、0.020,均P＜0.05＝.logistic回归分析提示,-765GG基因型是糖尿病肾病发生的独立危险因素之一[比值比（OR）=3.25,95%可信区间（CI）为1.336～7.901].结论 在昆明地区汉族2型糖尿病患者中,环氧化酶2基因启动子区-765GG基因型与糖尿病肾病的发生、发展有关.     

我国各地区医药制造业竞争力的比较分析

文章阐述了我国医药制造业的基本现状,对31个省市区(港、澳、台地区除外)的医药制造业竞争力,主要从市场占有率和市场竞争优势系数两个方面,进行了比较分析。市场占有率的优势主要集中在东部发达地区,但是市场竞争优势系数的优势分布较为均匀,各地区均有其自身的优势。     

Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan,leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: An AGEO randomised phase II study (FIRGEM)

BackgroundFluorouracil and irinotecan-based, and gemcitabine-based regimens, are the standard of care in the first-line treatment of patients with metastatic pancreatic cancer. New approaches are needed to improve survival and quality of life. Whether a sequential approach alternating irinotecan, fluorouracil and gemcitabine may be effective and tolerable in patients with metastatic pancreatic cancer is unknown.MethodsIn this randomised, multicentre, open-label, phase 2 trial, patients with metastatic pancreatic adenocarcinoma, World Health Organisation (WHO) performance status 0–1, and bilirubin levels <1.5 upper limit of normal values (ULN) were randomised 1:1 to receive as first-line treatment either FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) alternating with fixed-dose rate gemcitabine as 2-month periods (FIRGEM, arm A), or fixed-dose rate gemcitabine alone (arm B). Treatment was continued until disease progression or limiting toxicity. The primary end-point was the crude progression-free survival (PFS) rate at 6 months. The study is registered with EudraCT (N° 2006-005703-34).ResultsBetween October 2007 and March 2011, 98 patients were enroled. The observed 6-month PFS rate was 43.5% (95% confidence interval (CI), [28.6–58.4%]) in arm A reaching the Fleming decision rules criteria to reject H0 and 26.1% (95% CI [12.9–39.3%]) in arm B.Objective response rates were 37% (23–51%) in arm A and 10% (1–19%) in arm B. Median PFS (5.0 versus 3.4 months, hazard ratio (HR) = 0.59 [0.38–0.90]) and overall survival (11.0 versus 8.2 months, HR = 0.71 [0.46–1.10]) were higher in arm A compared to arm B. The most frequent grade 3–4 toxicities were neutropenia (49%/24%; febrile neutropenia, 4%/0% in arms A/B), diarrhoea (arm A, 12% and arm B, 0%), and nausea/vomiting (8%/4%). No toxic deaths occurred.ConclusionThe FIRGEM strategy appears to be effective and feasible in patients with metastatic pancreatic cancer.     

功能磁共振在精神障碍性疾病中的研究进展

功能磁共振成像(resting-state functional magnetic resonance imaging,fMR)l为探索脑工作机制和规律提供了一新思路和方法.其中联合应用静息态功能磁共振成像(fMR)I与弥散张量成像技术(DT)I,在探讨研究精神障碍性患者静息态功能连接与解剖连接的关系方面有一定临床价值.本文就功能磁共振在常见精神障碍性疾病方面的研究进行综述.     

89SrCl2治疗多发性骨髓瘤骨痛疗效分析

Objective: To evaluate the efficacy of 89SrCl2 in treatment of patients with multiple myeloma (MM). Methods: Thirty-three patients with phase III MM and bone pain were treated with 89SrCl2 once (4 mCi). KPS, VAS, radionuclide bone imaging, bone marrow and adverse effects were evaluated before and after treatment. Results: KPS scores raised and VAS scores decreased one month after treatment (both P<0.05). Three months after treatment, radionuclide bone imaging showed that the response rate of bone metastases was 39.4%, the stable rate was 42.4% and the non-response rate was 15.2%; there was no significant difference in the percentage of malignant plasma cells in bone marrow before and after treatment (P>0.05). No irreversible bone marrow depression was found. Conclusion: 89SrCl2 can be used to treat patients with MM as a safe and effective agent. © 2015, Journal of Practical Oncology, Editorial Board. All right reserved.     

HPLC法间接测定肿瘤患者外周血中二氢尿嘧啶脱氢酶的活性

目的:建立间接测定肿瘤患者外周血中二氢尿嘧啶脱氢酶(DPD)活性的方法。方法:采用高效液相色谱(HPLC)法测定肿瘤患者血浆中内源性物质二氢尿嘧啶(H2U)和尿嘧啶(U)的比值,间接估算DPD的活性。其中,色谱柱为XterraRPC18,流动相为甲醇-0.02mol·L-1磷酸二氢钠(pH4.0)(5:95),流速为1.0mL·min-1,检测波长分别为204nm(H2U)、260nm(U)。结果:H2U、U检测浓度分别在62.5～2000μg·L-1(r=0.9997)、15.625～500μg·L-1(r=0.9993)范围内线性关系良好,日内RSD分别≤7.7%、8.3%,日间RSD分别≤13.8%、13.4%,方法回收率分别为99.63%～103.02%、98.38%～109.08%。63例肿瘤患者的DPD活性(H2U/U比值)在肿瘤患者中变异较大,范围为1.51～6.67。结论:本方法可用于肿瘤患者外周血DPD活性的常规监测。